Darinaparsin in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cells Lines and SCID Xenograft Mouse Models: Single-Agent Activity and Synergistic Cell Death Combined with a PI3K/mTOR Inhibitor

被引：0
|
作者：
Dashnamoorthy, Ravi
Bhalla, Savita [1 ,2 ]
Crombie, Jennifer [3 ]
Kandela, Irawati [4 ]
Mazar, Andrew [4 ]
Evens, Andrew M. [5 ]
机构：
[1] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Northwestern Univ, Chem Life Proc Inst, Evanston, IL USA
[5] Univ Massachusetts, Sch Med, Div Hematol Oncol, Worcester, MA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1646.1646
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1646
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The 2nd Generation Proteasome Inhibitor, MLN2238: Potent Induction of Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and in Two Human Lymphoma Xenograft Models
    Dashnamoorthy, Ravi
    Kandela, Irawati
    Bhalla, Savita
    Galloway, Jasmine
    Zaretsky, Irina
    Mazar, Andrew
    Evens, Andrew M.
    [J]. BLOOD, 2012, 120 (21)
  • [2] The Novel Organic Arsenical, Darinaparsin (ZIO-101), Induces Apoptosis through AKT and MEK/ERK Pathways In Hodgkin Lymphoma (HL) and T-Cell Lymphoma (TCL) Cell Lines
    Bhalla, Savita
    Prachand, Sheila
    Gordon, Leo I.
    Evens, Andrew M.
    [J]. BLOOD, 2010, 116 (21) : 1171 - 1171
  • [3] THE NOVEL ORGANIC ARSENICAL, DARINAPARSIN (ZIO-101), INDUCES APOPTOSIS THROUGH AKT AND MEK/ERK PATHWAYS IN HODGKIN LYMPHOMA (HL) AND T-CELL LYMPHOMA (TCL) CELL LINES
    Bhalla, S.
    Prachand, S.
    Vidula, N.
    Gordon, L., I
    Evens, A. M.
    [J]. HAEMATOLOGICA, 2010, 95 : S11 - S12
  • [4] The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models
    Ravi, Dashnamoorthy
    Bhalla, Savita
    Gartenhaus, Ronald B.
    Crombie, Jennifer
    Kandela, Irawati
    Sharma, Jaya
    Mazar, Andrew
    Evens, Andrew M.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (23) : 6023 - 6033
  • [5] Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
    Horwitz, Steven M.
    Koch, Raphael
    Porcu, Pierluigi
    Oki, Yasuhiro
    Moskowitz, Alison
    Perez, Megan
    Myskowski, Patricia
    Officer, Adam
    Jaffe, Jacob D.
    Morrow, Sara N.
    Allen, Kerstin
    Douglas, Mark
    Stern, Howard
    Sweeney, Jennifer
    Kelly, Patrick
    Kelly, Virginia
    Aster, Jon C.
    Weaver, David
    Foss, Francine M.
    Weinstock, David M.
    [J]. BLOOD, 2018, 131 (08) : 888 - 898
  • [6] Proteasome and HDAC Inhibitor Therapy in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Nuclear Factor Erythroid 2 like 2 (NRF2)-Dependent Cell Death and Function
    Passero, Frank C., Jr.
    Dashnamoorthy, Ravi
    Beheshti, Afshin
    McDonald, J. Tyson
    Evens, Andrew M.
    [J]. BLOOD, 2016, 128 (22)
  • [7] The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach
    Coyle, Michael E.
    Dashnamoorthy, Ravi
    Beheshti, Afshin
    Evens, Andrew M.
    [J]. BLOOD, 2015, 126 (23)
  • [8] Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL)
    Dashnamoorthy, Ravi
    Behesti, Afshin
    Abermil, Nassera
    Sharma, Jaya
    Coyle, Michael
    Kandela, Irawati
    Mazar, Andrew
    Hlatky, Lynn
    Evens, Andrew M.
    [J]. BLOOD, 2014, 124 (21)
  • [9] Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis
    Locatelli, Silvia Laura
    Careddu, Giuseppa
    Chierchia, Armando
    Viswanadha, Srikant
    Vakkalanka, Swaroop
    Castagna, Luca
    Santoro, Armando
    Carlo-Stella, Carmelo
    [J]. BLOOD, 2015, 126 (23)
  • [10] The Bruton's Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/ Novel Therapeutic Combinations
    Cerulli, Robert A.
    Dashnamoorthy, Ravi
    Evens, Andrew M.
    [J]. BLOOD, 2014, 124 (21)
12345